Invention Grant
- Patent Title: Antisense-oligonucleotides as inhibitors of TGF-R signaling
-
Application No.: US15525561Application Date: 2015-11-16
-
Publication No.: US11213541B2Publication Date: 2022-01-04
- Inventor: Markus Hossbach , Monika Krampert , Hans-Lothar Arth
- Applicant: NeuroVision Pharma GmbH
- Applicant Address: DE Grünwald
- Assignee: NeuroVision Pharma GmbH
- Current Assignee: NeuroVision Pharma GmbH
- Current Assignee Address: DE Grünwald
- Agency: Knobbe, Martens, Olson & Bear LLP
- Priority: EP14193368 20141116
- International Application: PCT/EP2015/076730 WO 20151116
- International Announcement: WO2016/075339 WO 20160519
- Main IPC: C12N15/113
- IPC: C12N15/113 ; A61K9/00 ; A61P35/00 ; A61P43/00 ; A61K31/7125
Abstract:
The present invention relates to antisense-oligonucleotides having a length of at least 10 nucleotides, wherein at least two of the nucleotides are LNAs, their use as inhibitors of TGF-R signaling, pharmaceutical compositions containing such antisense-oligonucleotides and the use for prophylaxis and treatment of neurological, neurodegenerative, fibrotic and hyperproliferative diseases.
Public/Granted literature
- US20170319614A1 ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING Public/Granted day:2017-11-09
Information query
IPC分类:
